NEW YORK (GenomeWeb News) — OncoMethylome Sciences and Exact Sciences today said they plan to advance the sale of stool-based colorectal cancer-screening technologies through service labs in Europe and North America.
The agreement calls for Exact to grant OncoMethylome non-exclusive rights to its DNA-stabilization, -isolation, and -extraction technology for stool-based CRC-screening tests in Europe.
In exchange, OncoMethylome will pay royalties to Exact based on sales.
Separately, OncoMethylome will sell reagents to Exact, which may use them in stool-based CRC screening services in North America.
The reagents will enable Exact to detect methylation at certain DNA markers using MSP technology. The terms of the agreement also call for OncoMethylome to sell reagents to Exact’s commercial partners, subject to their negotiation with OncoMethylome.
Further financial details of the license and supply agreements were not disclosed.